Previous Close | 0.7699 |
Open | 0.7800 |
Bid | 0.7810 x 800 |
Ask | 0.8300 x 800 |
Day's Range | 0.7700 - 0.7999 |
52 Week Range | 0.5500 - 1.9800 |
Volume | |
Avg. Volume | 275,175 |
Market Cap | 49.656M |
Beta (5Y Monthly) | 1.27 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.7850 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.67 |
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript March 22, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx 2022 Financial Results Conference Call. I would now like to turn over the call to John Lacey, Head of Investor Relations and Corporate Communications BioLineRx. Please go ahead. John Lacey: Thank […]
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 2022 Operational and Financial Results On March 22, 2023, BioLineRx Ltd. (NASDAQ:BLRX) reported 2022 operational and financial results in a press release concurrent with the filing of Form 20-F . A conference call and webcast were hosted later that morning. Key highlights since the previous earnings update in November
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported its audited 2022 annual financial results for the year ended December 31, 2022, and provided recent corporate and portfolio updates.